2022 World Conference on Lung Cancer (ePosters)-EP08.02-114. Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

EP08.02-114. Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

Pdf Summary

This study aims to analyze the clinical and molecular characteristics of ROS1 gene mutations in non-small cell lung cancer (NSCLC) patients who do not have ROS1 fusions or solvent-front mutations (SFM) that lead to resistance to targeted therapy. The research was conducted using next-generation sequencing (NGS) on tissue samples from NSCLC patients. A total of 118 out of 8072 patients (1.5%) were found to have ROS1 mutations.<br /><br />The majority of the patients with ROS1 mutations were male (76.3%) and had adenocarcinoma histology (57.6%). The average age at diagnosis was 68 years, and almost all patients (96.5%) had a smoking history. Most patients presented with Eastern Cooperative Oncology Group’s (ECOG) performance state 1 at diagnosis. The majority of patients had stage IV NSCLC, followed by stage III.<br /><br />The study found that most ROS1 mutations were transversions, and there was no specific genomic hotspot region identified. In 10.2% of patients, ROS1 mutation was the only detected aberration. Analysis of PD-L1 expression showed that most tumors expressed 1-49% of PD-L1, while 36.3% of tumors expressed no PD-L1.<br /><br />Overall, this cohort of NSCLC patients with ROS1 mutations differed in clinical characteristics compared to patients with ROS1 fusions. The study suggests that these molecular subtypes have different clinical impacts and may have the potential to be targeted by drugs. Further research is needed to characterize the biological impact of these mutations and their potential as drug targets.<br /><br />The findings of this study provide valuable insights into the characteristics of NSCLC patients with ROS1 mutations and highlight the need for further investigation into this molecular subtype.

Asset Subtitle

Moritz Glaser

Meta Tag

Speaker Moritz Glaser

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

ROS1 gene mutations

non-small cell lung cancer

NSCLC patients

ROS1 fusions

solvent-front mutations

targeted therapy

next-generation sequencing

tissue samples

adenocarcinoma histology

smoking history